These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 12181402)
1. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402 [TBL] [Abstract][Full Text] [Related]
2. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders. Gallagher G; Horsman DE; Tsang P; Forrest DL Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053 [TBL] [Abstract][Full Text] [Related]
3. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms. Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582 [TBL] [Abstract][Full Text] [Related]
4. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078 [TBL] [Abstract][Full Text] [Related]
5. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975 [TBL] [Abstract][Full Text] [Related]
6. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479 [TBL] [Abstract][Full Text] [Related]
7. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Safley AM; Sebastian S; Collins TS; Tirado CA; Stenzel TT; Gong JZ; Goodman BK Genes Chromosomes Cancer; 2004 May; 40(1):44-50. PubMed ID: 15034867 [TBL] [Abstract][Full Text] [Related]
8. A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate. Wittman B; Horan J; Baxter J; Goldberg J; Felgar R; Baylor E; Cromwell B; Cross N; Bennett JM Leuk Res; 2004 May; 28 Suppl 1():S65-9. PubMed ID: 15036944 [TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Cross NC; Reiter A Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537 [TBL] [Abstract][Full Text] [Related]
10. Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene. Bastie JN; Garcia I; Terré C; Cross NC; Mahon FX; Castaigne S Haematologica; 2004 Oct; 89(10):1263-4. PubMed ID: 15477214 [TBL] [Abstract][Full Text] [Related]
11. Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report. Pitini V; Arrigo C; Teti D; Barresi G; Righi M; Alo G Haematologica; 2003 May; 88(5):ECR18. PubMed ID: 12745287 [TBL] [Abstract][Full Text] [Related]
12. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693 [TBL] [Abstract][Full Text] [Related]
13. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement. Arefi M; García JL; Peñarrubia MJ; Queizán JA; Hermosín L; López-Corral L; Megido M; Giraldo P; de las Heras N; Vanegas RJ; Gutiérrez NC; Hernández-Rivas JM Eur J Haematol; 2012 Jul; 89(1):37-41. PubMed ID: 22587685 [TBL] [Abstract][Full Text] [Related]
14. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion. Cavazzini F; Bardi A; Ciccone M; Rigolin GM; Gorello P; La Starza R; Mecucci C; Cuneo A Cancer Genet Cytogenet; 2009 Oct; 194(1):67-9. PubMed ID: 19737658 [No Abstract] [Full Text] [Related]
15. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151 [TBL] [Abstract][Full Text] [Related]
16. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854 [No Abstract] [Full Text] [Related]
17. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate. Rathe M; Kristensen TK; Møller MB; Carlsen NL Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620 [TBL] [Abstract][Full Text] [Related]
18. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088 [TBL] [Abstract][Full Text] [Related]
19. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377 [TBL] [Abstract][Full Text] [Related]
20. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate. Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]